期刊文献+

罗格列酮治疗42例溃疡性结肠炎的临床疗效分析 被引量:1

下载PDF
导出
摘要 目的分析罗格列酮治疗溃疡性结肠炎的临床疗效。方法选择84例在我院就诊的门诊及住院UC患者,随机分为治疗组和对照组,各42例。对照组采用柳氮磺胺吡啶进行治疗,1.0g口服,每日三次。治疗组在对照组基础上加用罗格列酮片4mg/日(规格:4mg/片)。一个月为一个疗程。结果显示治疗组改善情况明显优于对照组(P<0.05)。结论罗格列酮应用于UC治疗可增强PPAR-γ活性,抑制NF-KB等炎症转录因子的活性,从而提高UC抗炎疗效。
作者 葛洋
出处 《当代医学》 2009年第30期148-149,共2页 Contemporary Medicine
  • 相关文献

参考文献3

二级参考文献37

  • 1邓长生,夏冰,陈德基,周燕,龚玲玲,高志清.超氧化物歧化酶对大鼠乙酸性结肠炎粘膜的保护作用[J].中国病理生理杂志,1994,10(1):23-26. 被引量:31
  • 2马锋振,马洪升.炎症性肠病炎症过程中ICAM-1的表达及作用[J].世界华人消化杂志,2005,13(8):1014-1016. 被引量:6
  • 3Lefebvre AM, Paulweber B, Fajas L, Woods J, Mccrary C, Colombel JF, Najib J, Fruchart JC, Datz C, Vidal H, Desreumaux P, Auwerx J. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrin 1999, 162:331-340.
  • 4Cuzzorea S, Pisano B, Dugo L, Ianaro A, Maffia P,Patel NSA, Paola RD, Ialenti A, Genovese T, hatterjee PK, Rosa MD, Caputi AP, Thiemermann C.Rosiglitazone, a ligand of the peroxisome proliferator activated receptor-T, reduces acute inflammation. Eur J Pharmacol 2004, 483:79-93.
  • 5Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumaerg RS, Nagai R, Matsuhashi N.Endogenous PPAR y mediates anti-inflammatory acticity in murine ischemia-reperfusion injury. Gastroenterology 2001, 120:460-469.
  • 6Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.Inflamm Bowel Dis 2002,8:330-339.
  • 7Dubuquoy L, Jansson EA, Deeb S, Rakotobe S,Karoui M, Colombel JF, Auwerx J, Pettersson S,Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003,124:1265-1276.
  • 8Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schooljans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J. Attenuation of colon inflammation through activators of the retinoid x receptor(RXR)/peroxisome proliferator-activated receptory(PPAR)heterodimer: a basis for new therapeutic strategies.J Exp Med 2001, 193:827-838.
  • 9Wada K, Nakajima A, Blumberg RS. PPAR and inflammatory bowel disease:a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 2001, 7:329-331.
  • 10Wu GD. Is there a role for PPAR gamma in IBD?Yes, no, maybe. Gastroenterology 2003, 124:1538-1542.

共引文献19

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部